Cargando…

Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy

Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pocivalnik, Mirjam, Danda, Manfred, Urlesberger, Berndt, Raith, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313667/
https://www.ncbi.nlm.nih.gov/pubmed/30360382
http://dx.doi.org/10.3390/medicines5040113
_version_ 1783383986024742912
author Pocivalnik, Mirjam
Danda, Manfred
Urlesberger, Berndt
Raith, Wolfgang
author_facet Pocivalnik, Mirjam
Danda, Manfred
Urlesberger, Berndt
Raith, Wolfgang
author_sort Pocivalnik, Mirjam
collection PubMed
description Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of neonatal abstinence syndrome (NAS) can occur. Methods/Results: We report a term male infant suffering from a severe brief resolved unexplained event caused by his mother’s sertraline intake during pregnancy. Conclusions: Newborn infants exposed to selective serotonine reuptake inhibitors (SSRIs) during pregnancy should be evaluated very carefully concerning NAS and monitored for NAS symptoms for a minimum of 72–96 h, or until symptoms have fully recovered using standardized protocols. There is a risk of severe NAS symptoms which might occur, and this circumstance should be discussed with the parents and taken into account before administering the drug.
format Online
Article
Text
id pubmed-6313667
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63136672019-01-07 Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy Pocivalnik, Mirjam Danda, Manfred Urlesberger, Berndt Raith, Wolfgang Medicines (Basel) Case Report Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of neonatal abstinence syndrome (NAS) can occur. Methods/Results: We report a term male infant suffering from a severe brief resolved unexplained event caused by his mother’s sertraline intake during pregnancy. Conclusions: Newborn infants exposed to selective serotonine reuptake inhibitors (SSRIs) during pregnancy should be evaluated very carefully concerning NAS and monitored for NAS symptoms for a minimum of 72–96 h, or until symptoms have fully recovered using standardized protocols. There is a risk of severe NAS symptoms which might occur, and this circumstance should be discussed with the parents and taken into account before administering the drug. MDPI 2018-10-22 /pmc/articles/PMC6313667/ /pubmed/30360382 http://dx.doi.org/10.3390/medicines5040113 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Pocivalnik, Mirjam
Danda, Manfred
Urlesberger, Berndt
Raith, Wolfgang
Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title_full Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title_fullStr Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title_full_unstemmed Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title_short Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
title_sort severe brief resolved unexplained event in a newborn infant in association with maternal sertralin treatment during pregnancy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313667/
https://www.ncbi.nlm.nih.gov/pubmed/30360382
http://dx.doi.org/10.3390/medicines5040113
work_keys_str_mv AT pocivalnikmirjam severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy
AT dandamanfred severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy
AT urlesbergerberndt severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy
AT raithwolfgang severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy